Ultragenyx Stock Analysis

RARE
 Stock
  

USD 36.88  0.58  1.60%   

The latest dip in stock price created some momentum for shareholders as it was traded today as low as 36.39 and as high as 37.29 per share. The company directors and management have failed to build on market volatilities in November. However, diversifying your overall positions with Ultragenyx may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.3. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Ultragenyx partners.
Additionally, take a look at Your Equity Center.
  
The Ultragenyx stock analysis report makes it easy to digest most publicly released information about Ultragenyx and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ultragenyx Stock analysis module also helps to analyze the Ultragenyx price relationship with some important fundamental indicators such as market cap and management efficiency.

Ultragenyx Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 6.87. Ultragenyx had not issued any dividends in recent years. The entity had 1:3 split on the 17th of January 2014. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Ultragenyx Pharmaceu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1119 people. To find out more about Ultragenyx contact Emil Kakkis at 415 483 8800 or learn more at https://www.ultragenyx.com.

Ultragenyx Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ultragenyx's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ultragenyx or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ultragenyx generated a negative expected return over the last 90 days
Ultragenyx has high historical volatility and very poor performance
The company reported the previous year's revenue of 351.41 M. Net Loss for the year was (454.02 M) with loss before overhead, payroll, taxes, and interest of (161.75 M).
Ultragenyx currently holds about 542.8 M in cash with (338.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.75.
Ultragenyx has a poor financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Transcript Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 1000 AM - Marketscreener.com

Ultragenyx Upcoming and Recent Events

Earnings reports are used by Ultragenyx to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ultragenyx previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Ultragenyx Largest EPS Surprises

Earnings surprises can significantly impact Ultragenyx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-05-11
2015-03-31-0.54-0.63-0.0916 
2020-10-27
2020-09-30-1.26-1.130.1310 
2015-11-09
2015-09-30-0.87-1.03-0.1618 
View All Earnings Estimates

Ultragenyx Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.5 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ultragenyx's market, we take the total number of its shares issued and multiply it by Ultragenyx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ultragenyx Profitablity

Ultragenyx's profitability indicators refer to fundamental financial ratios that showcase Ultragenyx's ability to generate income relative to its revenue or operating costs. If, let's say, Ultragenyx is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ultragenyx's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ultragenyx's profitability requires more research than a typical breakdown of Ultragenyx's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.02.
Last ReportedProjected for 2022
Return on Investment(36.76) (39.66) 
Return on Average Assets(27.67) (29.85) 
Return on Average Equity(43.72) (47.17) 
Return on Invested Capital(0.61) (0.66) 
Return on Sales-1.7 K-1.8 K

Management Efficiency

The entity has return on total asset (ROA) of (0.244) % which means that it has lost $0.244 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.9669) %, meaning that it created substantial loss on money invested by shareholders. Ultragenyx management efficiency ratios could be used to measure how well ultragenyx manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2022, Return on Investment is expected to decline to -39.66. In addition to that, Return on Average Assets is expected to decline to -29.85. Ultragenyx Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 856.6 Million. The current year Assets Non Current is expected to grow to about 134.9 M, whereas Return on Average Assets are forecasted to decline to (29.85) .
Last ReportedProjected for 2022
Book Value per Share 10.46  11.28 
Enterprise Value over EBIT(9.90) (10.68) 
Enterprise Value over EBITDA(10.12) (10.92) 
Price to Book Value 6.97  7.88 
Tangible Assets Book Value per Share 15.24  21.21 
Enterprise Value2.5 B2.5 B
Tangible Asset Value486.6 M525 M

Technical Drivers

As of the 1st of December, Ultragenyx has the coefficient of variation of (801.46), and Risk Adjusted Performance of (0.18). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ultragenyx, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Ultragenyx, which can be compared to its competition. Please validate Ultragenyx jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if Ultragenyx is priced more or less accurately, providing market reflects its prevalent price of 36.88 per share. Given that Ultragenyx has jensen alpha of (0.51), we advise you to double-check Ultragenyx's current market performance to make sure the company can sustain itself at a future point.

Ultragenyx Price Movement Analysis

The output start index for this execution was three with a total number of output elements of fifty-eight. Ultragenyx Triple Exponential Moving Average indicator shows smoothing effect of Ultragenyx price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Ultragenyx Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ultragenyx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ultragenyx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ultragenyx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dier Mardi over a month ago via Macroaxis 
Sale by Dier Mardi of 3484 shares of Ultragenyx Pharmaceu
Dier Mardi over two months ago via Macroaxis 
Acquisition by Dier Mardi of 20000 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Deborah Dunsire over two months ago via Macroaxis 
Acquisition by Deborah Dunsire of 2145 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Huizenga Theodore Alan over two months ago via Macroaxis 
Acquisition by Huizenga Theodore Alan of 1000 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Sanders Corazon Corsee D over three months ago via Macroaxis 
Acquisition by Sanders Corazon Corsee D of 6245 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Ray Amrit over three months ago via Macroaxis 
Acquisition by Ray Amrit of 6245 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Erik Harris over three months ago via Macroaxis 
Sale by Erik Harris of 295 shares of Ultragenyx Pharmaceu
Ray Amrit over six months ago via Macroaxis 
Acquisition by Ray Amrit of 9525 shares of Ultragenyx Pharmaceu subject to Rule 16b-3
Huizenga Theodore Alan over six months ago via Macroaxis 
Sale by Huizenga Theodore Alan of 132 shares of Ultragenyx Pharmaceu
Thomas Kassberg over six months ago via Macroaxis 
Sale by Thomas Kassberg of 10281 shares of Ultragenyx Pharmaceu
Karah Parschauer over six months ago via Macroaxis 
Sale by Karah Parschauer of 5140 shares of Ultragenyx Pharmaceu
Camille Bedrosian over six months ago via Macroaxis 
Sale by Camille Bedrosian of 1657 shares of Ultragenyx Pharmaceu

Ultragenyx Predictive Daily Indicators

Ultragenyx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ultragenyx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ultragenyx Forecast Models

Ultragenyx time-series forecasting models is one of many Ultragenyx's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ultragenyx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ultragenyx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ultragenyx prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ultragenyx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Ultragenyx. By using and applying Ultragenyx Stock analysis, traders can create a robust methodology for identifying Ultragenyx entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(48.82) (52.67) 
Gross Margin 95.44  106.08 
Profit Margin(61.95) (66.84) 

Current Ultragenyx Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ultragenyx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ultragenyx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
143.93Buy15Odds
Ultragenyx current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ultragenyx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ultragenyx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ultragenyx, talking to its executives and customers, or listening to Ultragenyx conference calls.
Ultragenyx Analyst Advice Details

Ultragenyx Stock Analysis Indicators

Ultragenyx stock analysis indicators help investors evaluate how Ultragenyx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ultragenyx shares will generate the highest return on investment. By understating and applying Ultragenyx stock analysis, traders can identify Ultragenyx position entry and exit signals to maximize returns.
Begin Period Cash Flow726294000.00
Logo U R LimglogosUSrare.png
Common Stock Shares Outstanding60845550.00
Total Stockholder Equity922561000.00
DescriptionUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internation
Total Cashflows From Investing Activities-195372000.00
Tax Provision1044000.00
Property Plant And Equipment Net176183000.00
Retained Earnings-2073601000.00
Cash And Short Term Investments740196000.00
Retained Earnings Total Equity-2073601000.00
Cash307584000.00
CodeRARE
Accounts Payable17138000.00
Net Debt-265614000.00
50 Day M A38.612
Total Current Liabilities181368000.00
Currency CodeUSD
Other Operating Expenses733143000.00
Non Current Assets Total665793000.00
Common Stock Total Equity69000.00
Non Currrent Assets Other20558000.00
Additionally, take a look at Your Equity Center. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for analysis

When running Ultragenyx price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Ultragenyx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
2.5 B
Quarterly Revenue Growth YOY
0.11
Return On Assets
(0.24) 
Return On Equity
(0.97) 
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine Ultragenyx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.